STUDY PROTOCOL Randomised controlled, crossover trial to evaluate the Effects of Ambulatory Oxygen on health status in patients with Fibrotic Lung Disease (FLD) Sponsor’s R&D Registration Number: 2013OE005B Sponsor’s Details: Royal Brompton and Harefield NHS Foundation Trust (RB&HFT) EudraCT number: 2013-004355-20 CHI EF I NVESTI GATOR ( CI ) : Dr Elisabetta Renzoni Consultant Chest Physician Royal Brompton Hospital (RBH) Fulham Wing, Level M London SW3 6LR Phone: 0207 3528121 ext 3367 or 8327 Email: e.renzoni@rbht.nhs.uk or e.renzoni@imperial.ac.uk Fax: 0207 3518336 SPONSOR REPRESENTATI VE: Dr Angela Cooper Royal Brompton and Harefield NHS Foundation Trust (RB&HFT) Royal Brompton Hospital (RBH) Research Office Chelsea Wing, Level 2 Sydney Street London SW3 6NP Phone: 0207 352 8121 ext. 2610 Email: a.cooper@rbht.nhs.uk Fax: 020 8725 0794 Information in this protocol is confidential and should not be disclosed, other than to those directly involved in the execution or the ethical/regulatory review of the study, without written authorization from RB&HFT Research Office (RO) or its affiliates. Ambulatory Oxygen in Fibrotic Lung Disease Protocol V3.0, 1 st December 2014 RO ID Number: 2013OE005B Page 1 of 48